Line | Label | W | B | D-P | Value | Source | Message |
1 | Primary Concepts [http://www.SampleCompany.com/PrimaryConcepts] |
2 | Context D-2003-Agri[from 2003-01-01 to 2003-12-31 for SAMP] |
3 | U-Euros |
4 | primary:Revenue for Primary Segment, Total | | C | D 0 | 6,693,000,000 | both | OK |
5 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 6,693,000,000 | inst | |
|
6 | Context D-2003-AH[from 2003-01-01 to 2003-12-31 for SAMP] |
7 | U-Euros |
8 | primary:Revenue for Primary Segment, Total | | C | D 0 | 1,083,000,000 | both | OK |
9 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 1,083,000,000 | inst | |
10 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | 0 | inst | |
|
11 | Context D-2003-CH[from 2003-01-01 to 2003-12-31 for SAMP] |
12 | U-Euros |
13 | primary:Revenue for Primary Segment, Total | | C | D 0 | 6,556,000,000 | both | OK |
14 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 6,514,000,000 | inst | |
15 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | 42,000,000 | inst | |
|
16 | Context D-2003-CIBA[from 2003-01-01 to 2003-12-31 for SAMP] |
17 | U-Euros |
18 | primary:Revenue for Primary Segment, Total | | C | D 0 | 1,400,000,000 | both | OK |
19 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 1,392,000,000 | inst | |
20 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | 8,000,000 | inst | |
|
21 | Context D-2003-Continuing[from 2003-01-01 to 2003-12-31 for SAMP] |
22 | U-Euros |
23 | primary:Revenue for Primary Segment, Total | | C | D 0 | 29,112,000,000 | both | OK |
24 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 29,112,000,000 | inst | |
|
25 | Context D-2003-Corp[from 2003-01-01 to 2003-12-31 for SAMP] |
26 | U-Euros |
27 | primary:Revenue for Primary Segment, Total | | C | D 0 | (465,000,000) | both | OK |
28 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | (465,000,000) | inst | |
|
29 | Context D-2003-Discontinued[from 2003-01-01 to 2003-12-31 for SAMP] |
30 | U-Euros |
31 | primary:Revenue for Primary Segment, Total | | C | D 0 | 6,693,000,000 | both | OK |
32 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 6,693,000,000 | inst | |
|
33 | Context D-2003-Gen[from 2003-01-01 to 2003-12-31 for SAMP] |
34 | U-Euros |
35 | primary:Revenue for Primary Segment, Total | | C | D 0 | 2,143,000,000 | both | OK |
36 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 1,973,000,000 | inst | |
37 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | 170,000,000 | inst | |
|
38 | Context D-2003-Pharm[from 2003-01-01 to 2003-12-31 for SAMP] |
39 | U-Euros |
40 | primary:Revenue for Primary Segment, Total | | C | D 0 | 18,395,000,000 | both | OK |
41 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 18,150,000,000 | inst | |
42 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | 245,000,000 | inst | |
|
43 | Context D-2003-Total[from 2003-01-01 to 2003-12-31 for SAMP] |
44 | U-Euros |
45 | primary:Revenue for Primary Segment, Total | | C | D 0 | 35,805,000,000 | both | OK |
46 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 35,805,000,000 | inst | |
|
47 | Context D-2004-Agri[from 2004-01-01 to 2004-12-31 for SAMP] |
48 | U-Euros |
49 | primary:Revenue for Primary Segment, Total | | C | D 0 | 0 | both | OK |
50 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 0 | inst | |
|
51 | Context D-2004-AH[from 2004-01-01 to 2004-12-31 for SAMP] |
52 | U-Euros |
53 | primary:Revenue for Primary Segment, Total | | C | D 0 | 977,000,000 | both | OK |
54 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 962,000,000 | inst | |
55 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | 15,000,000 | inst | |
|
56 | Context D-2004-CH[from 2004-01-01 to 2004-12-31 for SAMP] |
57 | U-Euros |
58 | primary:Revenue for Primary Segment, Total | | C | D 0 | 6,704,000,000 | both | OK |
59 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 6,675,000,000 | inst | |
60 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | 29,000,000 | inst | |
|
61 | Context D-2004-CIBA[from 2004-01-01 to 2004-12-31 for SAMP] |
62 | U-Euros |
63 | primary:Revenue for Primary Segment, Total | | C | D 0 | 1,804,000,000 | both | OK |
64 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 1,787,000,000 | inst | |
65 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | 17,000,000 | inst | |
|
66 | Context D-2004-Continuing[from 2004-01-01 to 2004-12-31 for SAMP] |
67 | U-Euros |
68 | primary:Revenue for Primary Segment, Total | | C | D 0 | 32,038,000,000 | both | OK |
69 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 32,038,000,000 | inst | |
|
70 | Context D-2004-Corp[from 2004-01-01 to 2004-12-31 for SAMP] |
71 | U-Euros |
72 | primary:Revenue for Primary Segment, Total | | C | D 0 | (494,000,000) | both | OK |
73 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | (494,000,000) | inst | |
|
74 | Context D-2004-Discontinued[from 2004-01-01 to 2004-12-31 for SAMP] |
75 | U-Euros |
76 | primary:Revenue for Primary Segment, Total | | C | D 0 | 0 | both | OK |
77 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 0 | inst | |
|
78 | Context D-2004-Gen[from 2004-01-01 to 2004-12-31 for SAMP] |
79 | U-Euros |
80 | primary:Revenue for Primary Segment, Total | | C | D 0 | 2,636,000,000 | both | OK |
81 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 2,433,000,000 | inst | |
82 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | 203,000,000 | inst | |
|
83 | Context D-2004-Pharm[from 2004-01-01 to 2004-12-31 for SAMP] |
84 | U-Euros |
85 | primary:Revenue for Primary Segment, Total | | C | D 0 | 20,411,000,000 | both | OK |
86 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 20,181,000,000 | inst | |
87 | primary:Sales from Transactions with Other Segments for Segment | 1 | C | D 0 | 230,000,000 | inst | |
|
88 | Context D-2004-Total[from 2004-01-01 to 2004-12-31 for SAMP] |
89 | U-Euros |
90 | primary:Revenue for Primary Segment, Total | | C | D 0 | 32,038,000,000 | both | OK |
91 | primary:Sales to External Customers for Segment | 1 | C | D 0 | 32,038,000,000 | inst | |
|
92 | Context I-2003-Agri[at 2003-12-31 for SAMP] |
93 | U-Euros |
94 | primary:Equity and Liabilities, Total | | C | D 0 | 0 | both | OK |
95 | primary:Liabilities, Total | 1 | C | D 0 | 0 | inst | |
96 | primary:Equity, Total | 1 | C | D 0 | 0 | inst | |
|
97 | Context I-2003-AH[at 2003-12-31 for SAMP] |
98 | U-Euros |
99 | primary:Equity and Liabilities, Total | | C | D 0 | 842,000,000 | both | OK |
100 | primary:Liabilities, Total | 1 | C | D 0 | 198,000,000 | inst | |
101 | primary:Equity, Total | 1 | C | D 0 | 644,000,000 | inst | |
|
102 | Context I-2003-CH[at 2003-12-31 for SAMP] |
103 | U-Euros |
104 | primary:Equity and Liabilities, Total | | C | D 0 | 4,426,000,000 | both | OK |
105 | primary:Liabilities, Total | 1 | C | D 0 | 2,142,000,000 | inst | |
106 | primary:Equity, Total | 1 | C | D 0 | 2,284,000,000 | inst | |
|
107 | Context I-2003-CIBA[at 2003-12-31 for SAMP] |
108 | U-Euros |
109 | primary:Equity and Liabilities, Total | | C | D 0 | 3,169,000,000 | both | OK |
110 | primary:Liabilities, Total | 1 | C | D 0 | 824,000,000 | inst | |
111 | primary:Equity, Total | 1 | C | D 0 | 2,345,000,000 | inst | |
|
112 | Context I-2003-Continuing[at 2003-12-31 for SAMP] |
113 | U-Euros |
114 | primary:Equity and Liabilities, Total | | C | D 0 | 58,196,000,000 | both | OK |
115 | primary:Liabilities, Total | 1 | C | D 0 | 21,256,000,000 | inst | |
116 | primary:Equity, Total | 1 | C | D 0 | 36,940,000,000 | inst | |
|
117 | Context I-2003-Corp[at 2003-12-31 for SAMP] |
118 | U-Euros |
119 | primary:Equity and Liabilities, Total | | C | D 0 | 30,297,000,000 | both | OK |
120 | primary:Liabilities, Total | 1 | C | D 0 | 12,979,000,000 | inst | |
121 | primary:Equity, Total | 1 | C | D 0 | 17,318,000,000 | inst | |
|
122 | Context I-2003-Discontinued[at 2003-12-31 for SAMP] |
123 | U-Euros |
124 | primary:Equity and Liabilities, Total | | C | D 0 | 0 | both | OK |
125 | primary:Liabilities, Total | 1 | C | D 0 | 0 | inst | |
126 | primary:Equity, Total | 1 | C | D 0 | 0 | inst | |
|
127 | Context I-2003-Gen[at 2003-12-31 for SAMP] |
128 | U-Euros |
129 | primary:Equity and Liabilities, Total | | C | D 0 | 2,575,000,000 | both | OK |
130 | primary:Liabilities, Total | 1 | C | D 0 | 636,000,000 | inst | |
131 | primary:Equity, Total | 1 | C | D 0 | 1,939,000,000 | inst | |
|
132 | Context I-2003-Pharm[at 2003-12-31 for SAMP] |
133 | U-Euros |
134 | primary:Equity and Liabilities, Total | | C | D 0 | 16,887,000,000 | both | OK |
135 | primary:Liabilities, Total | 1 | C | D 0 | 4,477,000,000 | inst | |
136 | primary:Equity, Total | 1 | C | D 0 | 12,410,000,000 | inst | |
|
137 | Context I-2003-Total[at 2003-12-31 for SAMP] |
138 | U-Euros |
139 | primary:Equity and Liabilities, Total | | C | D 0 | 58,196,000,000 | both | OK |
140 | primary:Liabilities, Total | 1 | C | D 0 | 21,256,000,000 | inst | |
141 | primary:Equity, Total | 1 | C | D 0 | 36,940,000,000 | inst | |
|
142 | Context I-2004-Agri[at 2004-12-31 for SAMP] |
143 | U-Euros |
144 | primary:Equity and Liabilities, Total | | C | D 0 | 0 | both | OK |
145 | primary:Liabilities, Total | 1 | C | D 0 | 0 | inst | |
146 | primary:Equity, Total | 1 | C | D 0 | 0 | inst | |
|
147 | Context I-2004-AH[at 2004-12-31 for SAMP] |
148 | U-Euros |
149 | primary:Equity and Liabilities, Total | | C | D 0 | 735,000,000 | both | OK |
150 | primary:Liabilities, Total | 1 | C | D 0 | 163,000,000 | inst | |
151 | primary:Equity, Total | 1 | C | D 0 | 572,000,000 | inst | |
|
152 | Context I-2004-CH[at 2004-12-31 for SAMP] |
153 | U-Euros |
154 | primary:Equity and Liabilities, Total | | C | D 0 | 4,686,000,000 | both | OK |
155 | primary:Liabilities, Total | 1 | C | D 0 | 2,158,000,000 | inst | |
156 | primary:Equity, Total | 1 | C | D 0 | 2,528,000,000 | inst | |
|
157 | Context I-2004-CIBA[at 2004-12-31 for SAMP] |
158 | U-Euros |
159 | primary:Equity and Liabilities, Total | | C | D 0 | 2,909,000,000 | both | OK |
160 | primary:Liabilities, Total | 1 | C | D 0 | 599,000,000 | inst | |
161 | primary:Equity, Total | 1 | C | D 0 | 2,310,000,000 | inst | |
|
162 | Context I-2004-Continuing[at 2004-12-31 for SAMP] |
163 | U-Euros |
164 | primary:Equity and Liabilities, Total | | C | D 0 | 66,785,000,000 | both | OK |
165 | primary:Liabilities, Total | 1 | C | D 0 | 24,436,000,000 | inst | |
166 | primary:Equity, Total | 1 | C | D 0 | 42,349,000,000 | inst | |
|
167 | Context I-2004-Corp[at 2004-12-31 for SAMP] |
168 | U-Euros |
169 | primary:Equity and Liabilities, Total | | C | D 0 | 36,462,000,000 | both | OK |
170 | primary:Liabilities, Total | 1 | C | D 0 | 15,289,000,000 | inst | |
171 | primary:Equity, Total | 1 | C | D 0 | 21,173,000,000 | inst | |
|
172 | Context I-2004-Discontinued[at 2004-12-31 for SAMP] |
173 | U-Euros |
174 | primary:Equity and Liabilities, Total | | C | D 0 | 0 | both | OK |
175 | primary:Liabilities, Total | 1 | C | D 0 | 0 | inst | |
176 | primary:Equity, Total | 1 | C | D 0 | 0 | inst | |
|
177 | Context I-2004-Gen[at 2004-12-31 for SAMP] |
178 | U-Euros |
179 | primary:Equity and Liabilities, Total | | C | D 0 | 3,362,000,000 | both | OK |
180 | primary:Liabilities, Total | 1 | C | D 0 | 740,000,000 | inst | |
181 | primary:Equity, Total | 1 | C | D 0 | 2,622,000,000 | inst | |
|
182 | Context I-2004-Pharm[at 2004-12-31 for SAMP] |
183 | U-Euros |
184 | primary:Equity and Liabilities, Total | | C | D 0 | 18,631,000,000 | both | OK |
185 | primary:Liabilities, Total | 1 | C | D 0 | 5,487,000,000 | inst | |
186 | primary:Equity, Total | 1 | C | D 0 | 13,144,000,000 | inst | |
|
187 | Context I-2004-Total[at 2004-12-31 for SAMP] |
188 | U-Euros |
189 | primary:Equity and Liabilities, Total | | C | D 0 | 66,785,000,000 | both | OK |
190 | primary:Liabilities, Total | 1 | C | D 0 | 24,436,000,000 | inst | |
191 | primary:Equity, Total | 1 | C | D 0 | 42,349,000,000 | inst | |
|
192 | Dimensions period from 2003-01-01 to 2003-12-31 for SAMP |
193 | U-Euros |
194 | company:Operations (Placeholder)//operations:Continuing |
195 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | | D 0 | 1,179,000,000 | both | OK |
196 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | | D 0 | 534,000,000 | inst | |
197 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | | D 0 | 241,000,000 | inst | |
198 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | | D 0 | 122,000,000 | inst | |
199 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | | D 0 | 120,000,000 | inst | |
200 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | | D 0 | 20,000,000 | inst | |
201 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | | D 0 | 142,000,000 | inst | |
202 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 4,011,000,000 | both | OK |
203 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 3,311,000,000 | inst | |
204 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 170,000,000 | inst | |
205 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 186,000,000 | inst | |
206 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 67,000,000 | inst | |
207 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 88,000,000 | inst | |
208 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 189,000,000 | inst | |
209 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | (101,000,000) | both | OK |
210 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | (42,000,000) | inst | |
211 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | (16,000,000) | inst | |
212 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | (2,000,000) | inst | |
213 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | (41,000,000) | inst | |
214 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 0 | inst | |
215 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 0 | inst | |
216 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 6,727,000,000 | both | OK |
217 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 5,401,000,000 | inst | |
218 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 242,000,000 | inst | |
219 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 869,000,000 | inst | |
220 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 100,000,000 | inst | |
221 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 179,000,000 | inst | |
222 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | (64,000,000) | inst | |
223 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 29,112,000,000 | both | OK |
224 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 18,395,000,000 | inst | |
225 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 2,143,000,000 | inst | |
226 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 6,556,000,000 | inst | |
227 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 1,400,000,000 | inst | |
228 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 1,083,000,000 | inst | |
229 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | (465,000,000) | inst | |
230 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 205,000,000 | both | OK |
231 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 62,000,000 | inst | |
232 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 58,000,000 | inst | |
233 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 38,000,000 | inst | |
234 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 32,000,000 | inst | |
235 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 12,000,000 | inst | |
236 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 3,000,000 | inst | |
237 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 97,000,000 | both | OK |
238 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 104,000,000 | inst | |
239 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 1,000,000 | inst | |
240 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | (7,000,000) | inst | |
241 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | (1,000,000) | inst | |
242 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 0 | inst | |
243 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | 0 | inst | |
244 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 968,000,000 | both | OK |
245 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 622,000,000 | inst | |
246 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 115,000,000 | inst | |
247 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 101,000,000 | inst | |
248 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 86,000,000 | inst | |
249 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 12,000,000 | inst | |
250 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 32,000,000 | inst | |
251 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 2,000,000 | both | OK |
252 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 2,000,000 | inst | |
253 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 0 | inst | |
254 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 0 | inst | |
255 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 0 | inst | |
256 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 0 | inst | |
257 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 0 | inst | |
258 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 29,112,000,000 | both | OK |
259 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 18,150,000,000 | inst | |
260 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 1,973,000,000 | inst | |
261 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 6,514,000,000 | inst | |
262 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 1,392,000,000 | inst | |
263 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 1,083,000,000 | inst | |
|
264 | company:Operations (Placeholder)//operations:Discontinued |
265 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | | D 0 | 174,000,000 | both | OK |
266 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | | D 0 | 174,000,000 | inst | |
267 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 646,000,000 | both | OK |
268 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 646,000,000 | inst | |
269 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
270 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
271 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 1,156,000,000 | both | OK |
272 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 1,156,000,000 | inst | |
273 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 6,693,000,000 | both | OK |
274 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 6,693,000,000 | inst | |
275 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 104,000,000 | both | OK |
276 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 104,000,000 | inst | |
277 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 1,000,000 | both | OK |
278 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 1,000,000 | inst | |
279 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 221,000,000 | both | OK |
280 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 221,000,000 | inst | |
281 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 5,000,000 | both | OK |
282 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 5,000,000 | inst | |
283 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 6,693,000,000 | both | OK |
284 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 6,693,000,000 | inst | |
|
285 | company:Sectors (Placeholder)//sectors:Group |
286 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Operations (Placeholder)//operations:Total] | | | D 0 | 1,353,000,000 | both | OK |
287 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Operations (Placeholder)//operations:Continuing] | 1 | | D 0 | 1,179,000,000 | inst | |
288 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | | D 0 | 174,000,000 | inst | |
289 | primary:Profit (Loss)[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 7,252,000,000 | both | OK |
290 | primary:Profit (Loss)[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 6,536,000,000 | inst | |
291 | primary:Profit (Loss)[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 716,000,000 | inst | |
292 | primary:Profit (Loss) Attributable to Equity Holders of Parent[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 7,210,000,000 | both | OK |
293 | primary:Profit (Loss) Attributable to Equity Holders of Parent[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 6,511,000,000 | inst | |
294 | primary:Profit (Loss) Attributable to Equity Holders of Parent[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 699,000,000 | inst | |
295 | primary:Profit (Loss) Attributable to Minority Interest[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 42,000,000 | both | OK |
296 | primary:Profit (Loss) Attributable to Minority Interest[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 25,000,000 | inst | |
297 | primary:Profit (Loss) Attributable to Minority Interest[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 17,000,000 | inst | |
298 | primary:Profit (Loss) Before Tax[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 9,072,000,000 | both | OK |
299 | primary:Profit (Loss) Before Tax[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 8,040,000,000 | inst | |
300 | primary:Profit (Loss) Before Tax[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 1,032,000,000 | inst | |
301 | primary:Research and Development[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 4,657,000,000 | both | OK |
302 | primary:Research and Development[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 4,011,000,000 | inst | |
303 | primary:Research and Development[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 646,000,000 | inst | |
304 | primary:Restructuring Costs[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | (101,000,000) | both | OK |
305 | primary:Restructuring Costs[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | (101,000,000) | inst | |
306 | primary:Restructuring Costs[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
307 | primary:Result for Primary Segment[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 7,883,000,000 | both | OK |
308 | primary:Result for Primary Segment[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 6,727,000,000 | inst | |
309 | primary:Result for Primary Segment[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 1,156,000,000 | inst | |
310 | primary:Revenue for Primary Segment, Total[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 35,805,000,000 | both | OK |
311 | primary:Revenue for Primary Segment, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 29,112,000,000 | inst | |
312 | primary:Revenue for Primary Segment, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 6,693,000,000 | inst | |
313 | primary:Amortisation[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 309,000,000 | both | OK |
314 | primary:Amortisation[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 205,000,000 | inst | |
315 | primary:Amortisation[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 104,000,000 | inst | |
316 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 98,000,000 | both | OK |
317 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 97,000,000 | inst | |
318 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 1,000,000 | inst | |
319 | primary:Depreciation[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 1,189,000,000 | both | OK |
320 | primary:Depreciation[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 968,000,000 | inst | |
321 | primary:Depreciation[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 221,000,000 | inst | |
322 | primary:Finance Costs [for Non-Financial Activities][..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | (1,091,000,000) | both | OK |
323 | primary:Finance Costs [for Non-Financial Activities][..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | (1,216,000,000) | inst | |
324 | primary:Finance Costs [for Non-Financial Activities][..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 125,000,000 | inst | |
325 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 7,000,000 | both | OK |
326 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 2,000,000 | inst | |
327 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 5,000,000 | inst | |
328 | primary:Income Tax Expense (Income)[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 1,820,000,000 | both | OK |
329 | primary:Income Tax Expense (Income)[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 1,504,000,000 | inst | |
330 | primary:Income Tax Expense (Income)[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 316,000,000 | inst | |
331 | primary:Sales to External Customers for Segment[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 35,805,000,000 | both | OK |
332 | primary:Sales to External Customers for Segment[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 29,112,000,000 | inst | |
333 | primary:Sales to External Customers for Segment[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 6,693,000,000 | inst | |
|
334 | Dimensions period at 2003-12-31 for SAMP |
335 | U-Euros |
336 | company:Operations (Placeholder)//operations:Continuing |
337 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 9,030,000,000 | both | OK |
338 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 5,770,000,000 | inst | |
339 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 974,000,000 | inst | |
340 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 880,000,000 | inst | |
341 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 648,000,000 | inst | |
342 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 72,000,000 | inst | |
343 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 686,000,000 | inst | |
344 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 58,196,000,000 | both | OK |
345 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 16,887,000,000 | inst | |
346 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 2,575,000,000 | inst | |
347 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 4,426,000,000 | inst | |
348 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 3,169,000,000 | inst | |
349 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 842,000,000 | inst | |
350 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 30,297,000,000 | inst | |
351 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 58,196,000,000 | both | OK |
352 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 16,887,000,000 | inst | |
353 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 2,575,000,000 | inst | |
354 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 4,426,000,000 | inst | |
355 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 3,169,000,000 | inst | |
356 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 842,000,000 | inst | |
357 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | 30,297,000,000 | inst | |
358 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 1,531,000,000 | both | OK |
359 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 1,375,000,000 | inst | |
360 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 5,000,000 | inst | |
361 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 2,000,000 | inst | |
362 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 5,000,000 | inst | |
363 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 0 | inst | |
364 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 144,000,000 | inst | |
365 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 36,940,000,000 | both | OK |
366 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 12,410,000,000 | inst | |
367 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 1,939,000,000 | inst | |
368 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 2,284,000,000 | inst | |
369 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 2,345,000,000 | inst | |
370 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 644,000,000 | inst | |
371 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | 17,318,000,000 | inst | |
372 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 21,256,000,000 | both | OK |
373 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 4,477,000,000 | inst | |
374 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 636,000,000 | inst | |
375 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 2,142,000,000 | inst | |
376 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 824,000,000 | inst | |
377 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 198,000,000 | inst | |
378 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | 12,979,000,000 | inst | |
|
379 | company:Operations (Placeholder)//operations:Discontinued |
380 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
381 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
382 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
383 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
384 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 0 | both | OK |
385 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 0 | inst | |
386 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
387 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
388 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 0 | both | OK |
389 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 0 | inst | |
390 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 0 | both | OK |
391 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 0 | inst | |
|
392 | company:Sectors (Placeholder)//sectors:Group |
393 | primary:Property, Plant and Equipment, Net[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 9,030,000,000 | both | OK |
394 | primary:Property, Plant and Equipment, Net[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 9,030,000,000 | inst | |
395 | primary:Property, Plant and Equipment, Net[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
396 | primary:Assets, Total[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 58,196,000,000 | both | OK |
397 | primary:Assets, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 58,196,000,000 | inst | |
398 | primary:Assets, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
399 | primary:Equity and Liabilities, Total[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 58,196,000,000 | both | OK |
400 | primary:Equity and Liabilities, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 58,196,000,000 | inst | |
401 | primary:Equity and Liabilities, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
402 | primary:Equity Method Accounted Investments, Total[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 1,531,000,000 | both | OK |
403 | primary:Equity Method Accounted Investments, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 1,531,000,000 | inst | |
404 | primary:Equity Method Accounted Investments, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
405 | primary:Equity, Total[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 36,940,000,000 | both | OK |
406 | primary:Equity, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 36,940,000,000 | inst | |
407 | primary:Equity, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
408 | primary:Liabilities, Total[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 21,256,000,000 | both | OK |
409 | primary:Liabilities, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 21,256,000,000 | inst | |
410 | primary:Liabilities, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
|
411 | U-Pure |
412 | company:Operations (Placeholder)//operations:Continuing |
413 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Group] | | | D 0 | 67,653 | both | OK |
414 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | | D 0 | 38,397 | inst | |
415 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | | D 0 | 5,712 | inst | |
416 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | | D 0 | 12,949 | inst | |
417 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | | D 0 | 7,644 | inst | |
418 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | | D 0 | 1,975 | inst | |
419 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | | D 0 | 976 | inst | |
|
420 | company:Operations (Placeholder)//operations:Discontinued |
421 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Group] | | | D 0 | 0 | both | OK |
422 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | | D 0 | 0 | inst | |
|
423 | company:Sectors (Placeholder)//sectors:Group |
424 | primary:Number of Employees at End of Period[..., company:Operations (Placeholder)//operations:Total] | | | D 0 | 67,653 | both | OK |
425 | primary:Number of Employees at End of Period[..., company:Operations (Placeholder)//operations:Continuing] | 1 | | D 0 | 67,653 | inst | |
426 | primary:Number of Employees at End of Period[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | | D 0 | 0 | inst | |
|
427 | Dimensions period from 2004-01-01 to 2004-12-31 for SAMP |
428 | U-Euros |
429 | company:Operations (Placeholder)//operations:Continuing |
430 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | | D 0 | 1,351,000,000 | both | OK |
431 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | | D 0 | 617,000,000 | inst | |
432 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | | D 0 | 209,000,000 | inst | |
433 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | | D 0 | 129,000,000 | inst | |
434 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | | D 0 | 153,000,000 | inst | |
435 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | | D 0 | 19,000,000 | inst | |
436 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | | D 0 | 224,000,000 | inst | |
437 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 4,189,000,000 | both | OK |
438 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 3,447,000,000 | inst | |
439 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 169,000,000 | inst | |
440 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 181,000,000 | inst | |
441 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 98,000,000 | inst | |
442 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 93,000,000 | inst | |
443 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 201,000,000 | inst | |
444 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | (21,000,000) | both | OK |
445 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 0 | inst | |
446 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 0 | inst | |
447 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | (21,000,000) | inst | |
448 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 0 | inst | |
449 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 0 | inst | |
450 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 0 | inst | |
451 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 7,277,000,000 | both | OK |
452 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 5,677,000,000 | inst | |
453 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 281,000,000 | inst | |
454 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 920,000,000 | inst | |
455 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 174,000,000 | inst | |
456 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 138,000,000 | inst | |
457 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | 87,000,000 | inst | |
458 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 32,038,000,000 | both | OK |
459 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 20,411,000,000 | inst | |
460 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 2,636,000,000 | inst | |
461 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 6,704,000,000 | inst | |
462 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 1,804,000,000 | inst | |
463 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 977,000,000 | inst | |
464 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | (494,000,000) | inst | |
465 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 564,000,000 | both | OK |
466 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 306,000,000 | inst | |
467 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 87,000,000 | inst | |
468 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 45,000,000 | inst | |
469 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 102,000,000 | inst | |
470 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 15,000,000 | inst | |
471 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 9,000,000 | inst | |
472 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 139,000,000 | both | OK |
473 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 190,000,000 | inst | |
474 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 2,000,000 | inst | |
475 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | (14,000,000) | inst | |
476 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 0 | inst | |
477 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 0 | inst | |
478 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | (39,000,000) | inst | |
479 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 939,000,000 | both | OK |
480 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 578,000,000 | inst | |
481 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 126,000,000 | inst | |
482 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 105,000,000 | inst | |
483 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 96,000,000 | inst | |
484 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 14,000,000 | inst | |
485 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 20,000,000 | inst | |
486 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 246,000,000 | both | OK |
487 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 242,000,000 | inst | |
488 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 0 | inst | |
489 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 4,000,000 | inst | |
490 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 0 | inst | |
491 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 0 | inst | |
492 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 0 | inst | |
493 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 32,038,000,000 | both | OK |
494 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 20,181,000,000 | inst | |
495 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 2,433,000,000 | inst | |
496 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 6,675,000,000 | inst | |
497 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 1,787,000,000 | inst | |
498 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 962,000,000 | inst | |
|
499 | company:Operations (Placeholder)//operations:Discontinued |
500 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | | D 0 | 0 | both | OK |
501 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | | D 0 | 0 | inst | |
502 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
503 | primary:Research and Development[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
504 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
505 | primary:Restructuring Costs[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
506 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 0 | both | OK |
507 | primary:Result for Primary Segment[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 0 | inst | |
508 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 0 | both | OK |
509 | primary:Revenue for Primary Segment, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 0 | inst | |
510 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
511 | primary:Amortisation[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
512 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 0 | both | OK |
513 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 0 | inst | |
514 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
515 | primary:Depreciation[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
516 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
517 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
518 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 0 | both | OK |
519 | primary:Sales to External Customers for Segment[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 0 | inst | |
|
520 | company:Sectors (Placeholder)//sectors:Group |
521 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Operations (Placeholder)//operations:Total] | | | D 0 | 1,351,000,000 | both | OK |
522 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Operations (Placeholder)//operations:Continuing] | 1 | | D 0 | 1,351,000,000 | inst | |
523 | primary:Accrual-Based Capital Additions for Primary Segment[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | | D 0 | 0 | inst | |
524 | primary:Profit (Loss)[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 7,043,000,000 | both | OK |
525 | primary:Profit (Loss)[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 7,043,000,000 | inst | |
526 | primary:Profit (Loss)[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
527 | primary:Profit (Loss) Attributable to Equity Holders of Parent[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 7,024,000,000 | both | OK |
528 | primary:Profit (Loss) Attributable to Equity Holders of Parent[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 7,024,000,000 | inst | |
529 | primary:Profit (Loss) Attributable to Equity Holders of Parent[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
530 | primary:Profit (Loss) Attributable to Minority Interest[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 19,000,000 | both | OK |
531 | primary:Profit (Loss) Attributable to Minority Interest[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 19,000,000 | inst | |
532 | primary:Profit (Loss) Attributable to Minority Interest[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
533 | primary:Profit (Loss) Before Tax[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 8,483,000,000 | both | OK |
534 | primary:Profit (Loss) Before Tax[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 8,483,000,000 | inst | |
535 | primary:Profit (Loss) Before Tax[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
536 | primary:Research and Development[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 4,189,000,000 | both | OK |
537 | primary:Research and Development[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 4,189,000,000 | inst | |
538 | primary:Research and Development[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
539 | primary:Restructuring Costs[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | (21,000,000) | both | OK |
540 | primary:Restructuring Costs[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | (21,000,000) | inst | |
541 | primary:Restructuring Costs[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
542 | primary:Result for Primary Segment[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 7,277,000,000 | both | OK |
543 | primary:Result for Primary Segment[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 7,277,000,000 | inst | |
544 | primary:Result for Primary Segment[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
545 | primary:Revenue for Primary Segment, Total[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 32,038,000,000 | both | OK |
546 | primary:Revenue for Primary Segment, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 32,038,000,000 | inst | |
547 | primary:Revenue for Primary Segment, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
548 | primary:Amortisation[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 564,000,000 | both | OK |
549 | primary:Amortisation[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 564,000,000 | inst | |
550 | primary:Amortisation[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
551 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 139,000,000 | both | OK |
552 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 139,000,000 | inst | |
553 | primary:Share of Profit (Loss) from Equity-Accounted Investments for Primary Segment[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
554 | primary:Depreciation[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 939,000,000 | both | OK |
555 | primary:Depreciation[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 939,000,000 | inst | |
556 | primary:Depreciation[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
557 | primary:Finance Costs [for Non-Financial Activities][..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | (1,067,000,000) | both | OK |
558 | primary:Finance Costs [for Non-Financial Activities][..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | (1,067,000,000) | inst | |
559 | primary:Finance Costs [for Non-Financial Activities][..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
560 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 246,000,000 | both | OK |
561 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 246,000,000 | inst | |
562 | primary:Impairment Loss Recognised Directly into Equity for Primary Segment[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
563 | primary:Income Tax Expense (Income)[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 1,440,000,000 | both | OK |
564 | primary:Income Tax Expense (Income)[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 1,440,000,000 | inst | |
565 | primary:Income Tax Expense (Income)[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
566 | primary:Sales to External Customers for Segment[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 32,038,000,000 | both | OK |
567 | primary:Sales to External Customers for Segment[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 32,038,000,000 | inst | |
568 | primary:Sales to External Customers for Segment[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
|
569 | Dimensions period at 2004-12-31 for SAMP |
570 | U-Euros |
571 | company:Operations (Placeholder)//operations:Continuing |
572 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 9,060,000,000 | both | OK |
573 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 5,897,000,000 | inst | |
574 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 1,081,000,000 | inst | |
575 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 893,000,000 | inst | |
576 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 579,000,000 | inst | |
577 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 73,000,000 | inst | |
578 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 537,000,000 | inst | |
579 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 66,785,000,000 | both | OK |
580 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 18,631,000,000 | inst | |
581 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 3,362,000,000 | inst | |
582 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 4,686,000,000 | inst | |
583 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 2,909,000,000 | inst | |
584 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 735,000,000 | inst | |
585 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 36,462,000,000 | inst | |
586 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 66,785,000,000 | both | OK |
587 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 18,631,000,000 | inst | |
588 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 3,362,000,000 | inst | |
589 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 4,686,000,000 | inst | |
590 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 2,909,000,000 | inst | |
591 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 735,000,000 | inst | |
592 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | 36,462,000,000 | inst | |
593 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 6,715,000,000 | both | OK |
594 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | D | D 0 | 1,554,000,000 | inst | |
595 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | D | D 0 | 7,000,000 | inst | |
596 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | D | D 0 | 0 | inst | |
597 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | D | D 0 | 0 | inst | |
598 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | D | D 0 | 0 | inst | |
599 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | D | D 0 | 5,154,000,000 | inst | |
600 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 42,349,000,000 | both | OK |
601 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 13,144,000,000 | inst | |
602 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 2,622,000,000 | inst | |
603 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 2,528,000,000 | inst | |
604 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 2,310,000,000 | inst | |
605 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 572,000,000 | inst | |
606 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | 21,173,000,000 | inst | |
607 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 24,436,000,000 | both | OK |
608 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | C | D 0 | 5,487,000,000 | inst | |
609 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | C | D 0 | 740,000,000 | inst | |
610 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | C | D 0 | 2,158,000,000 | inst | |
611 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | C | D 0 | 599,000,000 | inst | |
612 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | C | D 0 | 163,000,000 | inst | |
613 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | C | D 0 | 15,289,000,000 | inst | |
|
614 | company:Operations (Placeholder)//operations:Discontinued |
615 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
616 | primary:Property, Plant and Equipment, Net[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
617 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
618 | primary:Assets, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
619 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 0 | both | OK |
620 | primary:Equity and Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 0 | inst | |
621 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Group] | | D | D 0 | 0 | both | OK |
622 | primary:Equity Method Accounted Investments, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | D | D 0 | 0 | inst | |
623 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 0 | both | OK |
624 | primary:Equity, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 0 | inst | |
625 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Group] | | C | D 0 | 0 | both | OK |
626 | primary:Liabilities, Total[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | C | D 0 | 0 | inst | |
|
627 | company:Sectors (Placeholder)//sectors:Group |
628 | primary:Property, Plant and Equipment, Net[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 9,060,000,000 | both | OK |
629 | primary:Property, Plant and Equipment, Net[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 9,060,000,000 | inst | |
630 | primary:Property, Plant and Equipment, Net[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
631 | primary:Assets, Total[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 66,785,000,000 | both | OK |
632 | primary:Assets, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 66,785,000,000 | inst | |
633 | primary:Assets, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
634 | primary:Equity and Liabilities, Total[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 66,785,000,000 | both | OK |
635 | primary:Equity and Liabilities, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 66,785,000,000 | inst | |
636 | primary:Equity and Liabilities, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
637 | primary:Equity Method Accounted Investments, Total[..., company:Operations (Placeholder)//operations:Total] | | D | D 0 | 6,715,000,000 | both | OK |
638 | primary:Equity Method Accounted Investments, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | D | D 0 | 6,715,000,000 | inst | |
639 | primary:Equity Method Accounted Investments, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | D | D 0 | 0 | inst | |
640 | primary:Equity, Total[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 42,349,000,000 | both | OK |
641 | primary:Equity, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 42,349,000,000 | inst | |
642 | primary:Equity, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
643 | primary:Liabilities, Total[..., company:Operations (Placeholder)//operations:Total] | | C | D 0 | 24,436,000,000 | both | OK |
644 | primary:Liabilities, Total[..., company:Operations (Placeholder)//operations:Continuing] | 1 | C | D 0 | 24,436,000,000 | inst | |
645 | primary:Liabilities, Total[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | C | D 0 | 0 | inst | |
|
646 | U-Pure |
647 | company:Operations (Placeholder)//operations:Continuing |
648 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Group] | | | D 0 | 71,116 | both | OK |
649 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Pharmaceuticals] | 1 | | D 0 | 41,256 | inst | |
650 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Generics] | 1 | | D 0 | 7,230 | inst | |
651 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Consumer Health] | 1 | | D 0 | 12,824 | inst | |
652 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:CIBA Vision] | 1 | | D 0 | 6,797 | inst | |
653 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Animal Health] | 1 | | D 0 | 1,997 | inst | |
654 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Corporate] | 1 | | D 0 | 1,012 | inst | |
|
655 | company:Operations (Placeholder)//operations:Discontinued |
656 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Group] | | | D 0 | 0 | both | OK |
657 | primary:Number of Employees at End of Period[..., company:Sectors (Placeholder)//sectors:Agribusiness] | 1 | | D 0 | 0 | inst | |
|
658 | company:Sectors (Placeholder)//sectors:Group |
659 | primary:Number of Employees at End of Period[..., company:Operations (Placeholder)//operations:Total] | | | D 0 | 71,116 | both | OK |
660 | primary:Number of Employees at End of Period[..., company:Operations (Placeholder)//operations:Continuing] | 1 | | D 0 | 71,116 | inst | |
661 | primary:Number of Employees at End of Period[..., company:Operations (Placeholder)//operations:Discontinued] | 1 | | D 0 | 0 | inst | |